From exposure to discovery: How SWATH DIA can enhance our understanding of the exposome and its impact on health by Rebekah Sayers | Mar 5, 2025 | Blogs, Life Science Research, ZenoTOF 7600 systemLast year, Technology Networks hosted two webinars that featured groundbreaking research utilizing SWATH DIA (data-independent acquisition) for exposomics and metabolomics. Researchers Dr. Vinicius Verri Hernandes from the University of Vienna and Dr. Cristina Balcells from Imperial College London (ICL) demonstrated how a DIA approach can be successfully implemented in small molecule analysis using the ZenoTOF 7600 system. Their innovative approaches highlight the potential of SWATH DIA to enhance the detection and analysis of chemical exposures and metabolites, paving the way for new insights into environmental health and disease mechanisms.
Unveiling the power of ZT Scan DIA: Insights from Ludwig Sinn’s presentation at World HUPO Congress 2024 by Rebekah Sayers | Feb 7, 2025 | Blogs, Life Science Research, Proteomics, ZenoTOF 7600 systemIn a recent presentation at the World HUPO Congress 2024, Ludwig Sinn from the Ralser lab shared exciting advancements in proteomics research, focusing on the innovative ZT Scan DIA acquisition modes developed in collaboration with SCIEX. Let us explore the key highlights and benefits of this innovative technology.
Inside the box: Complementary fragmentation with LC-MS for Metabolite Identification by Kirsten Craven | Feb 7, 2025 | Blogs, Pharma, ZenoTOF 7600 systemLiquid chromatography-mass spectrometry is commonly used for Met ID but confident soft spot identification is not always possible. Imagine the advantage of unambiguous metabolite identification using liquid chromatography-mass spectrometry (LC-MS) reducing the need for additional safety testing during drug discovery. Quickly and easily generate the information you need using routine assays that are robust and efficient, enabling confident decision-making while also saving time and money.
Pharma perspectives: The influence of LC-MS innovation on drug development outsourcing by Kean Woodmansey | Jan 13, 2025 | Blogs, Pharma, ZenoTOF 7600 systemIt is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Working for a contract research organization and more recently for SCIEX has provided an interesting perspective on trends the market experiences that affect many of us.
Selecting an LC-MS system for quantitation of pharmaceutical drug development by Kirsten Craven | Oct 29, 2024 | Blogs, Echo MS, Pharma, QTRAP / Triple Quad, ZenoTOF 7600 systemWe understand you are busy, needing to prioritize running instruments, reporting results and managing your laboratory to meet deadlines. We created a solution guide to explain how SCIEX systems fit in the drug development pipeline to save you time evaluating options.
An overview: LC-MS analysis of targeted protein degraders and their metabolites by Kirsten Craven | Aug 14, 2024 | Blogs, Pharma, ZenoTOF 7600 systemTargeted protein degraders (TPD) are a relatively new therapeutic modality that opens the potential to target disease-causing proteins. These disease-causing proteins have been highly challenging for traditional small-molecule therapeutics to treat, making TPDs an exciting new therapeutic modality.
Pure and simple: Understanding LNP analytics for better mRNA-based drugs by Kerstin Pohl | Jul 3, 2024 | Biopharma, Blogs, ZenoTOF 7600 systemA few years ago, it was discovered that messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNPs) could result in mRNA adducts due to the breakdown products of N-oxide impurities. The ionizable lipids used in LNPs are especially susceptible to forming N-oxide impurities.
A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics by Kerstin Pohl | Apr 29, 2024 | Biopharma, Blogs, Pharma, QTOF, QTRAP / Triple Quad, ZenoTOF 7600 systemIn 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.
Guide decisions during cell line development with more information at the intact level by Roxana McCloskey | Mar 28, 2024 | Biopharma, Blogs, Intabio ZT system, ZenoTOF 7600 systemMonitoring product quality attributes (PQAs) throughout monoclonal antibody (mAb) development is vital to ensuring drug safety and efficacy. By adopting orthogonal analytical techniques and integrating new technologies that have the potential to provide more information, it is possible to improve product quality and manufacturing efficiency and make more informed decisions.
Better mRNA-LNPs: encapsulation efficiency, mRNA integrity and purity, lipid N-oxides and beyond by Kerstin Pohl | Mar 14, 2024 | Biopharma, BioPhase 8800 system, Blogs, ZenoTOF 7600 systemLipid nanoparticles (LNPs) are widely used vehicles for mRNA-based therapeutics and vaccines. However, ionizable lipids used in LNPs can be susceptible to N-oxide impurities that can cause functional loss of the mRNA cargo.